Welcome to our dedicated page for Viemed Healthcare news (Ticker: VMD), a resource for investors and traders seeking the latest updates and insights on Viemed Healthcare stock.
Viemed Healthcare, Inc. provides technology-enabled, home-based healthcare solutions and chronic disease management in the United States. Company news centers on home medical equipment and post-acute healthcare services, including respiratory care, non-invasive ventilation, sleep and resupply offerings, oxygen therapy, chronic care, and women's health products and services delivered with clinical support in the home.
Recurring updates include quarterly and annual financial results, guidance, revenue mix, patient-start trends, capital expenditure expectations, share repurchase activity, investor presentations, and analyst coverage. Viemed's releases also discuss service-line diversification, medical equipment rental, sales and supply revenue, reimbursement and coverage documentation dynamics, and the contribution of its 2025 acquisition of Lehan's Medical Equipment.
Viemed Healthcare (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming First Quarter 2025 Earnings Conference Call. The call is scheduled for Thursday, May 8, 2025, at 11:00 a.m. EDT.
Participants can join via phone using US Toll-Free (866) 682-6100 or International +1 (862) 298-0702. A live audio webcast will be available, and a replay will be accessible in the Investor Relations section of Viemed's website after the call.
Viemed Healthcare (NASDAQ:VMD) reported record financial results for Q4 and full-year 2024. The company achieved Q4 net revenues of $60.7 million, up 20% year-over-year, while full-year revenues reached $224.3 million, increasing 23% from 2023.
Q4 net income was $4.3 million ($0.10 per diluted share), up 24% YoY, with full-year net income at $11.3 million ($0.28 per diluted share), marking the eighth consecutive year of profitability. The company expanded its patient base significantly, with ventilator patients up 14% to 11,795, PAP therapy patients up 43% to 21,338, and sleep resupply patients up 29% to 24,478.
For 2025, Viemed projects net revenue between $254-265 million and adjusted EBITDA of $54-58 million. The company maintains a strong financial position with $17.5 million in cash and $55 million available in credit facilities.
Viemed Healthcare (NASDAQ: VMD), a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming Year End 2024 earnings conference call. The call is scheduled for Tuesday, March 11, 2025, at 11:00 a.m. EDT.
Interested participants can join the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International). A live audio webcast will also be available through a dedicated link.
Following the live call, a replay will be accessible in the Investor Relations section of Viemed's website at www.viemed.com. This announcement allows investors and analysts to prepare for the company's presentation of its financial results and performance for the full year 2024.
Viemed Healthcare reported strong Q3 2024 financial results with net revenues increasing 17.4% to $58.0 million, setting a company record. Net income rose 33% to $3.9 million ($0.10 per diluted share), while Adjusted EBITDA grew 15.5% to $14.0 million. The company expanded its ventilator patient count by 11.0% to 11,374 and increased sleep therapy patients by 11.0% to 19,478. With a strong cash balance of $11.3 million and $55.3 million available in credit facilities, Viemed projects Q4 2024 revenues between $59.7-60.9 million, exceeding previous guidance.
Viemed Healthcare, a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming third quarter 2024 earnings conference call. The call is scheduled for Thursday, November 7, 2024, at 12:00 p.m. EST.
Interested parties can participate in the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International). A live audio webcast will also be available. Following the live call, a replay will be accessible in the Investor Relations section of Viemed's website at www.viemed.com.
Viemed Healthcare (NASDAQ:VMD) reported record second quarter 2024 financial results, with net revenues reaching $55.0 million, a 27% increase year-over-year and 9% sequential growth. The company achieved a net income of $1.5 million and Adjusted EBITDA of $12.8 million, up 31% from Q2 2023. Viemed's ventilator patient count grew to 10,905, a 4.4% sequential increase. The company maintains a strong financial position with $8.8 million in cash and $13.5 million in working capital. For Q3 2024, Viemed expects net revenues between $56.5 million and $57.7 million. CEO Casey Hoyt emphasized the company's strategy validation and leading position in complex respiratory care services.
Viemed Healthcare, a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming Quarterly Conference Call. The call is scheduled for Thursday, August 8, 2024, at 11:00 a.m. ET.
Interested parties can participate by dialing 888-437-3179 (US Toll-Free) or +1 862-298-0702 (International). Financial professionals are invited to pre-register by emailing investorinfo@viemed.com by 12:00 p.m. ET on Wednesday, August 7, 2024, to ask questions during the call.
A live audio webcast will be available, and following the call, a replay can be accessed in the Investor Relations section of Viemed's website.
Viemed Healthcare, Inc. announced its first quarter 2024 financial results, reporting net revenues of $50.6 million, a 28% increase from the same quarter last year. The company achieved a net income of $1.6 million and adjusted EBITDA of $10.1 million. Viemed also has a strong cash balance of $7.3 million, no net debt, and approximately $53 million available under credit facilities. The recent strategic partnership with East Alabama Health is expected to generate net revenues of $53.8-$54.8 million in the second quarter of 2024. CEO Casey Hoyt expressed optimism about the company's performance, highlighting investments in personnel, operational enhancements, and acquisition strategies.
Summary not available.
Summary not available.